CAPRELSA (Vandetanib) tablets for daily oral administration are available in two dosage strengths containing either 100 mg or 300 mg of vandetanib. The tablet cores contain the following inactive ingredients: calcium hydrogen phosphate dihydrate, microcrystalline cellulose, crospovidone, povidone, and magnesium stearate. The tablet film-coat contains the following inactive ingredients: hypromellose 2910, macrogol 300, and titanium dioxide E171.
Capsules: 40 mg.
300 mg once daily *CAPRELSA may be taken with or without food. Dosage reduction may be necessary in the event of severe toxicities or QTc interval prolongation. *The starting dose is 200 mg in patients with moderate to severe renal impairment.
CAPRELSA is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease